I believe now is a prime opportunity to buy HUMA while it's down. With FDA approval and a huge upside potential reflected in analyst targets, I see si...
Read
More
I believe now is a prime opportunity to buy HUMA while it's down. With FDA approval and a huge upside potential reflected in analyst targets, I see significant growth ahead for this innovative company in regenerative medicine. Don't miss out on this dip before it rebounds!
With the commercial launch of Symvess and FDA approval, I believe Humacyte is set for significant growth in 2025. Their new manufacturing patent furth...
Read
More
With the commercial launch of Symvess and FDA approval, I believe Humacyte is set for significant growth in 2025. Their new manufacturing patent further strengthens their market position, making this an opportune time to hold onto shares and potentially increase my position.
I just bought 210 calls for HUMA at a $4.50 strike expiring on 1/17. With FDA approval for their SYMVESS and a huge total addressable market, I believ...
Read
More
I just bought 210 calls for HUMA at a $4.50 strike expiring on 1/17. With FDA approval for their SYMVESS and a huge total addressable market, I believe the stock is undervalued right now despite the short-seller narratives. This company has strong backing and a solid business case going forward.
With Humacyte receiving full FDA approval for SYMVESS™, this is a game changer for the company. The new product addresses a critical medical need and ...
Read
More
With Humacyte receiving full FDA approval for SYMVESS™, this is a game changer for the company. The new product addresses a critical medical need and positions HUMA for significant growth. I'm bullish on this stock and plan to hold over the coming months.